Abstract:

Based on network pharmacology and experimental verification, the improvement of Rhodiola cernulata（R. crenulata） on skin telangiectasia was investigated to provide scientific basis for its comprehensive utilization in cosmetics, food and other fields. The active ingredients of R. cernulata were retrieved from SymMap and TCMIP database. Targets related to R. crenulata and skin telangiectasia were predicted using Swiss Target Prediction and Genecards database. The interactions between proteins were analyzed using String and the KEGG signaling pathways enrichment analysis were performed further. Finally, in vitro cell experiments were used to preliminarily verify the improvement of R. crenulate on skin telangiectasia. A total of 14 active ingredients of R. crenulata are selected to obtain 253 corresponding targets and 2 646 targets related to skin telangiectasia, of which 164 are intersection targets. The results of KEGG pathway enrichment analysis show that R. crenulata may play a role in inhibiting skin telangiectasia through Ras, VEGF, HIF-1, and other signaling pathways related to angiogenesis. In vitro cell experiment results show that R. crenulata extract can significantly inhibit the secretion of VEGF in keratinocytes （HaCaT） induced by TNF-α, and it further inhibit the proliferation, migration and formation of tubular structures of human umbilical can vein endothelial cells （HUVEC） induced by VEGF, which reflect the potential value of R. crenulata in treating skin telangiectasia.

Key words: Rhodiola cernulata, network pharmacology, telangiectasia, angiogenesis